中药复方防治肝癌作用机制研究进展

徐菲; 曾杨丽; 李娟; 蔡思; 唐玺; 王智; 肖利辉; 李顺祥

doi:10.13422/j.cnki.syfjx.20191921

您当前的位置：

首页 >

文章列表页 >

中药复方防治肝癌作用机制研究进展

综述 | 更新时间：2021-02-09

- 中药复方防治肝癌作用机制研究进展
- Mechanism of Traditional Chinese Medicine Compound in Preventing and Treating Hepatocellular Carcinoma
- 中国实验方剂学杂志 2019年25卷第24期页码：196-204
- 作者机构：
  
  1.湖南中医药大学，湖南省中药活性物质筛选工程技术研究中心，长沙　 410208；
  2.康普药业股份有限公司，长沙　 410008
- 作者简介：
  
  徐菲，在读博士，实验师，从事中药及其复方制剂物质基础与作用机制研究，E-mail：springxufei@163.com
  李顺祥，博士，二级教授，从事中药有效成分及中药新药研究，E-mail：lishunxiang@hotmail.com
- 基金信息：
  
  湖南中医药大学中药学一流学科项目(校行科字[2018]3号);湖南省科技计划项目(2016SK2033);长沙市科技局计划项目(kp1801043);湖南省中医药管理局重点项目(201614);湖南中医药大学中药学一流学科开放基金项目(2018ZYX02);湖南省教育厅项目(14C0861)
- DOI：10.13422/j.cnki.syfjx.20191921
  中图分类号： R22; R242; R2-031; R285.5; R287
- 纸质出版日期：2019-12-20，
  
  网络出版日期：2019-06-14，
  
  收稿日期：2018-12-03，
- 稿件说明：
扫描看全文
徐菲, 曾杨丽, 李娟, 等. 中药复方防治肝癌作用机制研究进展[J]. 中国实验方剂学杂志, 2019,25(24):196-204.

Fei XU, Yang-li ZENG, Juan LI, et al. Mechanism of Traditional Chinese Medicine Compound in Preventing and Treating Hepatocellular Carcinoma[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2019,25(24):196-204.
徐菲, 曾杨丽, 李娟, 等. 中药复方防治肝癌作用机制研究进展[J]. 中国实验方剂学杂志, 2019,25(24):196-204. DOI： 10.13422/j.cnki.syfjx.20191921.

Fei XU, Yang-li ZENG, Juan LI, et al. Mechanism of Traditional Chinese Medicine Compound in Preventing and Treating Hepatocellular Carcinoma[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2019,25(24):196-204. DOI： 10.13422/j.cnki.syfjx.20191921.

摘要

肝细胞癌是世界上最常见的恶性肿瘤。尽管肝癌在诊断和治疗方面取得了一些进展，但由于不易被早期诊断并且病情进程快，仍然是全球癌症死亡的第三大原因。中国亦是肝癌的高发地区，发病人数较多且呈上升趋势，防治形势相当严峻。目前，西医对于肝癌复杂发病机制与临床治疗思路尚不清晰，仍然存在许多短板并面临着巨大的挑战，而中医药在治疗肝癌方面具有其独特的优势，讲究整体观念，对于肝癌的治疗功效独特、副作用相对较小；不仅可以抑制肿瘤生长，还能改善患者的临床症状并提高其生存质量。因此，中医药方剂治疗肝癌的研究吸引了无数临床工作者和科研学者们的目光。但是中药复方的化学成分复杂，作用靶点多，发挥药效机制网络庞大，极大地限制了学者们对其的深入研究与临床用药开发。近年来，中药复方在抗肝癌的药效与作用机制研究方面也取得了一些成果，主要集中在复方对肝癌细胞的抑制增殖作用、阻滞细胞周期和诱导细胞凋亡与自噬作用、抑制肝癌细胞侵袭和转移、调节免疫功能、增效减毒和逆转耐药性等方面。该文对中药复方抗肝癌上述药效与作用机制的国内外文献进行检索，并进行分析、归纳与总结，现就其抗肝癌的作用机制研究进展作简要综述，为今后中药复方抗肝癌的作用机制研究及其临床合理应用提供科学思路与依据。

Abstract

Hepatocellular carcinoma(HCC) is the most common malignancy in the world. Although there is progress in HCC diagnosis and treatment

it is still the third leading cause of cancer death worldwide because it is not easily diagnosed early and the disease progresses quickly. China is a high-risk area for HCC

and the number of cases is high and on the rise. Its prevention and treatment is a pressing problem. At present

western medicine is still unclear about the complex pathogenesis and clinical treatment of HCC. There are still many shortcomings and huge challenges. Traditional Chinese medicine(TCM) has its unique advantages in the treatment of HCC. With an overall concept

it has unique therapeutic effect and fewer side effect on HCC

it can not only inhibit tumor growth

but also alleviate patients' clinical symptoms and improve their quality of life. Therefore

the study of the effect of TCM in treating HCC has attracted the attention from many clinicians and researchers. However

the chemical composition of TCM formula is complex

with many targets and huge network of pharmacodynamic mechanisms

which greatly limits the research on the development of clinical drugs for the Chinese medicine formula. In recent years

there have been achievements in the studies of anti-hepatocarcinoma efficacy and mechanism of action of Chinese medicine compound

which mainly focused on the compound's effect in inhibiting the proliferation of hepatocarcinoma cells

blocking cell cycle and inducing apoptosis and autophagy

inhibiting liver cancer cell invasion and metastasis

regulating the immune function

synergism and attenuation

and reversing the drug resistance. In this paper

domestic and foreign literatures on the above-mentioned pharmacodynamics and mechanism of anti-liver cancer of TCM compound were studied

analyzed

summarized and summarized. This paper briefly reviews the research progress of its anti-hepatocarcinoma mechanism

and provides scientific ideas and evidence for the future study of the anti-hepatocarcinoma mechanism of TCM compound and its rational clinical application.

关键词

中药复方防治肝癌肝细胞癌抑制肝癌肿瘤作用机制

Keywords

traditional Chinese medicine compoundprevention and treatment of liver cancerhepatocellular carcinomainhibiting liver cancer tumorsmechanism

references

Gaetano B, Shirin D, Annalisa A, et al. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies [J].Biomed Res Int, 2015, 2015(3): 1-12.

CHEN W, ZHENG R, Baade P D, et al. Cancer statistics in China, 2015 [J].CA Cancer J Clin, 2016, 66(2): 115-132.

杨婉婷，侯恩存．原发性肝癌治疗的研究进展[J]．现代肿瘤医学，2016，24(21)：3495-3499．

贺珊，廖长秀．中药治疗肝癌机制的研究进展[J]．中成药，2017，39(1)：155-160．

汪猛，秦凯健，杨梦琪，等．原发性肝癌的中医药诊治研究进展[J]．中医药导报，2015，21(3)：49-52．

程玉佩，张明香．中医药治疗原发性肝癌研究进展[J]．辽宁中医药大学学报，2018，20(1)：167-169．

HU B, AN H M, WANG S S, et al. Preventive and therapeutic effects of chinese herbal compounds against hepatocellular carcinoma [J].Molecules, 2016, 21(2): 142.

占义平，凌昌全．原发性肝癌中医证候研究概述[J]．中医杂志，2017，58(2)：167-170．

王斌．中西医结合治疗原发性肝癌研究进展[J]．临床医药文献电子杂志，2017，4(9)：19003．

梁慧，潘敏求．潘敏求教授治疗肿瘤经验和学术思想总结[J]．湖南中医杂志，2012，28(2)：22-24．

郑阳阳，陈宇，孟宪生，等．双莲方抗肝癌细胞SMMC-7721有效组分配伍研究[J]．中药材，2015，38(10)：2144-2147．

李然，刘立萍，马骥，等．小柴胡汤含药血清对肝癌 HepG-2细胞的影响[J]．中国实验方剂学杂志，2013，19(5)：217-220．

ZHAO J, LIU L, ZHANG Y, et al. The herbal mixture XIAO-CHAI-HU TANG (XCHT) induces apoptosis of human hepatocellular carcinoma Huh7 cells in vitro and in vivo [J].Evid-Based Complalt, 2017, 14(3): 231-241.

CAO Z Y, CHEN X Z, LIAO L M, et al. Fuzheng yiliu granule inhibits the growth of hepatocellular cancer by regulating immune function and inducing apoptosis in vivo and in vitro [J].Chin J Integr Med, 2011, 17(9): 691-697.

曾普华，郜文辉，潘敏求，等．益气化瘀解毒方药对人肝癌HepG2 细胞增殖和裸鼠移植瘤生长的影响[J]．现代肿瘤医学，2014，22(1)：8-11．

赵冬耕，孙佳，王明艳，等．抗癌扶正方对人肝癌细胞SMMC-7721 PI3K/Akt信号通路的影响[J]．中国实验方剂学杂志，2012，18(11)：136-139．

CHEN X Z, CAO Z Y, LI J N, et al. Ethyl acetate extract from Jiedu Xiaozheng Yin inhibits the proliferation of human hepatocellular carcinoma cells by suppressing polycomb gene product Bmi1 and Wnt/β-catenin signaling [J].Oncol Rep, 2014, 32(6): 2710-2718.

SUN B, MENG J, XIANG T, et al. Jianpijiedu fang improves survival of hepatocarcinoma mice by affecting phosphatase and tensin homolog, phosphoinositide 3-kinase, and focal adhesion kinase [J].Tradit Chin Med, 2013, 33(4): 479-485.

凌博凡，侯茜，邹玺，等．健脾化瘀方对肝癌耐药细胞P-糖蛋白的影响[J]．中华中医药杂志，2015，30(7)：2577-2580．

刘小美，潘志强，方肇勤，等．黄连-大黄-肉桂复方对肝癌细胞增殖及PTEN-PI3K-Akt/SGK1信号通路的影响[J]．上海中医药大学学报，2016，30(1)：50-54．

杜欣芸，李常青，陈滨，等．叶下珠复方Ⅱ号对肝癌Huh7细胞增殖、凋亡与自噬的影响[J]．中国实验方剂学杂志，2019，25(2)：48-54．

刘宏杰，陈建杰．黄芪四君子汤含药血清对人肝癌细胞增殖、迁移和凋亡的影响[J]．山东医药，2014，54(26)：22-24．

吕祥，李柏，凌昌全，等．四君子汤对小鼠H22肝癌细胞肺转移的作用[J]．浙江中医药大学学报，2010，34(6)：839-841．

YANG Y, XU S, HE S, et al. Compound astragalus and salvia miltiorrhiza extract inhibits cell invasion by modulating transforming growth factor-β/Smad in HepG2 cell [J].J Gastroenterol Hepatol, 2010, 25(2): 420-426.

CHEN T, WANG Q, LI Y, et al. Chinese herbal formula QHF inhibits liver cancer cell invasion and migration [J].Exp Ther Med, 2016, 11(6): 2413-2419.

王萍，姬生威，朱晓东，等．QHF复方对人肝癌Huh7细胞生长凋亡、侵袭能力的作用及其对肿瘤干细胞表面标志物的影响[J]．胃肠病学和肝病学杂志，2018，27(10)：1173-1176．

孙燕，张爱琴，郜飞宇．芍药软肝合剂对荷H22肝癌小鼠免疫功能及 VEGF、PCNA 表达的影响[J]．中国中医急症，2015，24(4)：590-592．

李俊立，丁月妮．二黄解郁汤对肝癌HepG2细胞生长抑制及 MMP-2表达的影响[J]．湖北医药学院学报，2012，31(1)：46-48，97．

蒋媛媛，徐扬，李媛媛，等．中药复方双术油抗肿瘤机制的研究[J]．中国实验方剂学杂志，2013，19(8)：258-261．

马星，夏伟．中药抗肝癌细胞增殖和诱导细胞凋亡的信号通路研究进展[J]．上海中医药杂志，2018，52(8)：98-101．

Babichev Y, Kabaroff L, Datti A, et al. PI3K/Akt/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma [J].J Transl Med, 2016, 14(1): 67-71.

OU D L, Lee B S, LIN L I, et al. Vertical blockade of the IGFR-PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin [J].Mol Cancer, 2014, 13(1): 1-11.

Riquelme I, Tapia O, Leal P, et al. miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/Akt/mTOR pathway [J].Cel Onco, 2016, 39(1): 23-33.

HU Y L, KUO P L, ZENG T F, et al. Huang-lian-jie-du-tang, a traditional Chinese medicine prescription, induces cell-cycle arrest and apoptosis in human liver cancer cells in vitro, and in vivo [J].J Gastroenterol Hepatol, 2008, 23(7pt2): e290-e299.

WANG N, FENG Y, TAN H Y, et al. Inhibition of eukaryotic elongation factor-2 confers to tumor suppression by a herbal formulation Huanglian-Jiedu decoction in human hepatocellular carcinoma [J].J Ethnopharmacol, 2015, 164: 309-318.

常欣峰，宋春花，陈涛，等．鳖甲煎丸对人肝癌细胞Bel-7402MAPK信号通路的影响[J]．赣南医学院学报，2015，35(5)：663-666，672．

文彬，孙海涛，贺松其，等．鳖甲煎丸对 HepG2 裸鼠移植瘤的抑制作用及瘤体组织中 β-catenin、Tbx3 表达水平的影响[J]．南方医科大学学报，2016，36(2)：210-214，219．

Babichev Y, Kabaroff L, Datti A, et al. PI3K/Akt/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma [J].J Transl Med, 2016, 14(1): 67-71.

CHO D C. Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook [J].Biodrugs, 2014, 28(4): 373-381.

LIU Y Z, WU K, HUANG J, et al. The PTEN/PI3K/Akt and Wnt/I^ 2-catenin signaling pathways are involved in the inhibitory effect of resveratrol on human colon cancer cell proliferation [J].Int J Oncol, 2014, 45(1): 104-112.

胡娜，王静．芪苓益肝颗粒在慢性肝病中JAK-STAT信号通路介导的分子作用机制研究[J]．中西医结合肝病杂志，2018，28(5)：300-303．

CHOU C C, PAN S L, TENG C M, et al. Pharmacological evaluation of several major ingredients of Chinese herbal medicines in human hepatoma Hep3B cells [J].Eur J Pharm Sci, 2003, 19(5): 403-412.

张蕾，周杰，骆俊，等．桑葚花色苷诱导人胃癌 SGC-7901 细胞自噬凋亡的研究[J]．中药材，2016，39(5)：1134-1138．

Watanabe R, Fujii H, Shirai T, et al. Autophagy plays a protective role as an anti-oxidant system in human T cells and represents a novel strategy for induction of T-cell apoptosis [J].Eur J Immunol, 2014, 44(8): 2508-2520.

WANG Y, JING L, et al. Autophagy in the “inflammation-carcinogenesis” pathway of liver and HCC immunotherapy [J].Cancer Lett, 2017, 411: 82-89.

杨爱琳，夏天吉，赵亚楠，等．槐耳清膏通过激活自噬抑制人肝癌细胞SK-HEP-1增殖[J]．中国中药杂志，2018，43(3)：591-595．

Valastyan S, Weinberg R A. Tumor metastasis: molecular insights and evolving paradigms [J].Cell, 2011, 147(2): 275-292.

Kunanopparat A, Issara-Amphorn J, Leelahavanichkul A, et al. Delta-like ligand 4 in hepatocellular carcinoma intrinsically promotes tumour growth and suppresses hepatitis B virus replication [J].World J Gastroentero, 2018, 24(34): 3861-3870.

Kumar A, Coleman I, Morrissey C, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer [J].Nat Med, 2016, 22(4): 369-378.

WANG S, XU X, ZHANG W, et al. Effects of Erbie San on Walker-256 liver cancer and adjustment to unbalance of VEGF/endostatin in rats [J].China J Chin Mater Med, 2009, 34(1): 89.

贺珊，廖长秀．基于信号转导通路的中药抗肝癌侵袭转移机制的研究进展[J]．世界华人消化杂志，2016，24(15)：2347-2354．

CHEN S R, QIU H C, HU Y, et al. Herbal medicine offered as an initiative therapeutic option for the management of hepatocellular carcinoma [J].Phytother Res, 2016, 30(6): 863-877.

胡兵，安红梅，王双双，等．养肝解毒散结中药对肝癌血管生成作用及机制[J]．中西医结合肝病杂志，2017，27(3)：158-160，199．

CHEN X, CAO Z, ZHANG G Y, et al. Fuzheng Qingjie granules inhibit growth of hepatoma cells via inducing mitochondria-mediated apoptosis and enhancing immune function [J].Integr Cancer Ther, 2017, 16(3): 329-338.

CHEN X Z, LI J N, ZHANG Y Q, et al. Fuzheng qingjie recipe induces apoptosis in HepG2 cells via P38 MAPK activation and the mitochondria-dependent apoptotic pathway [J].Mol Med Rep, 2014, 9(6): 2381-2387.

WANG X, WANG N, CHENG F, et al. Chinese medicines for prevention and treatment of human hepatocellular carcinoma: current progress on pharmacological actions and mechanisms [J].J Integr Med, 2015, 13 (3): 142-164.

LING C, YUE X. Three advantages of using traditional chinese medicine to prevent and treat tumor [J].Integr Med, 2014, 12 (4): 331-335.

吴婷婷，吴伟忠，高东梅，等．补肾健脾方抑制裸鼠高转移原位肝癌切除术后肿瘤复发以及对索拉非尼的增效减毒作用[J]．上海中医药杂志，2015，49(9)：63-66，76．

李敏，王斌，肖思源，等．扶正消癥方对环磷酰胺治疗S180荷瘤小鼠的增效减毒作用[J]．吉林中医药，2017，37(6)：604-607．

万海军．疏肝健脾方治疗原发性肝癌介入化疗后的临床研究[D]．南京：南京中医药大学，2015．

赵河通，翟笑枫．中药复方治疗原发性肝癌的临床研究进展[J]．中医药导报，2017，23(17)：107-110．

潘博．潘敏求主任医师治疗肝癌经验[J]．湖南中医杂志，2011，27(3)：46-48．

贺新春．肝复乐胶囊加常规治疗乙型肝炎肝硬化效果观察[J]．人民军医，2016，59(7)：714-715．

窦春青，金鑫，孙丽媛，等．肝复乐胶囊联合索拉非尼治疗晚期肝癌的临床研究[J]．现代药物与临床，2017，32(4)：644-647．

冯雨薇．张建军教授防治肝癌的经验总结及扶正解毒散结方治疗肝癌的临床研究[D]．武汉：湖北中医药大学，2018．

高映浩．扶正消积化瘀丸联合射波刀治疗原发性肝癌临床观察[D]．南宁：广西中医药大学，2018．

石相如，章凯敏，徐晓娅．益气活血中药对肝癌放疗后肝脏微循环及肝纤维化指标的影响[J]．世界中医药，2018，13(5)：1123-1126．

董孟佳．健脾活血方联合TACE治疗肝癌的临床疗效观察及抗肿瘤作用的实验研究[D]．南京：南京中医药大学，2018．

ZHAO C Q, ZHOU Y, PING J, et al. Traditional chinese medicine for treatment of liver diseases: progress, challenges and opportunities [J].J Integr Med, 2014, 12 (5): 401-408.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

肝细胞癌脂质代谢重编程及中药干预的研究进展

运脾化浊方对Wilson病铜稳态影响及机制

葛根芩连汤及其加减方改善2型糖尿病胰岛素抵抗作用研究进展

四君子汤调控肝癌癌旁组织NF-κB p65的O-GlcNAc糖基化修饰抑制肝细胞癌进展的机制

MAPK信号通路在防治类风湿关节炎中的作用及中药干预研究进展